Martín Jesús Pérez, Martinez Héctor Gerardo Acuña, Pérez Gerardo López, Manzur José N Reynés
Departamento de Educación Médica Continua, Instituto Nacional de Pediatría, colonia Insurgentes Cuicuilco, México.
Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9.
Allergic rhinitis, conjunctivitis and urticaria are very frequent diseases during childhood and adult age. Second generation H1 antihistamine drugs are considered first-line treatment due to their efficacy and safety.
To assess the efficacy and adverse effects of mequitazine in the treatment of these diseases.
A bibliographic systematic review was done in order to identify the efficacy of mequitazine in the treatment of allergic rhinitis and chronic urticaria in pediatric population. This paper reviews the pharmacological features of this drug and summarizes the eleven articles that may serve as reference to review systematically in the population mentioned. Search sources were: Medline database via PubMed, Google and Cochrane Collaboration. Key words were: mequitazine, antihistamine drugs (safety, efficacy and adverse effects). Articles published in several countries with translations to English and Spanish were included. Studies were selected based on their relevance in the treatment of the diseases mentioned with the H1 antihistamine drug mequitazine. Articles were searched by title and abstract, then, the full text, from 1975 to 2006. Two researchers selected the articles for this review.
We obtained 109 articles, from which 11 were first selected. Systematic review of articles demonstrated that mequitazine is effective and safe in the treatment of allergic rhinitis and chronic urticaria, their adverse effects are minimal and did not cause treatment cessation. Its efficacy and safety are comparable to those of other first- and second-generation antihistamine drugs.
Mequitazine is useful for the relieve of rhinoconjunctivitis and urticaria symptoms in more than 75% of patients; however, studies done so far have included only populations with adults predominance, thus, performing clinical studies in children is justified.
变应性鼻炎、结膜炎和荨麻疹是儿童期及成人期非常常见的疾病。第二代H1抗组胺药物因其有效性和安全性被视为一线治疗药物。
评估美喹他嗪治疗这些疾病的疗效和不良反应。
进行了一项文献系统评价,以确定美喹他嗪治疗儿童变应性鼻炎和慢性荨麻疹的疗效。本文回顾了该药物的药理学特性,并总结了11篇可作为系统评价上述人群参考的文章。检索来源包括:通过PubMed的Medline数据库、谷歌和Cochrane协作网。关键词为:美喹他嗪、抗组胺药物(安全性、有效性和不良反应)。纳入了在多个国家发表并翻译成英文和西班牙文的文章。根据H1抗组胺药物美喹他嗪在治疗上述疾病中的相关性选择研究。通过标题和摘要检索文章,然后检索1975年至2006年的全文。两名研究人员选择了纳入本评价的文章。
我们获得了109篇文章,从中首先筛选出11篇。文章的系统评价表明,美喹他嗪治疗变应性鼻炎和慢性荨麻疹有效且安全,其不良反应极小,未导致治疗中断。其有效性和安全性与其他第一代和第二代抗组胺药物相当。
美喹他嗪可缓解超过75%患者的鼻结膜炎和荨麻疹症状;然而,迄今为止所做的研究仅纳入了以成年人为主的人群,因此,在儿童中开展临床研究是合理的。